Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 3513 - 3520 of 12142 results

President Biden Rescinds Muslim travel bans
January 26, 2021| Blog| Viewpoint

Monthly TCPA Digest — January 2021
January 25, 2021| Article| Viewpoint

TCPA Regulatory Update — Busy End of 2020, Early 2021 as FCC Continues Traced Act Implementation & Takes Other Actions on Robocalls and Spoofing
January 25, 2021| Article| Viewpoint

TCPA Litigation Update — The Newest TCPA Circuit Split – And It Started With Creasy
January 25, 2021| Article| Viewpoint

Fifth Circuit Vacates $4.3M HIPAA Penalty and Potentially Opens the Door for Future HIPAA Enforcement Challenges
January 25, 2021| Blog| Viewpoint

The Impact of the Consolidated Appropriations Act on Flexible Spending Arrangements
January 25, 2021| Blog| Viewpoint

Beyond Extenders: What Might the “Blue Wave” Mean for Renewables Tax Legislation? (Part Two)
January 25, 2021| News

President Biden's Immigration Plan Legalizes Millions of Undocumented Workers
January 22, 2021| News
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts

Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
